Company intelligence / Profile preview

Wuxi Kejin Biotechnology

Wuxi, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Kejin Biotech is a clinical-stage biotechnology company based in Wuxi, China, specializing in the development of next-generation immune cell therapies for solid tumors. The company focuses on CAR-T and TCR-T technologies, leveraging its proprietary platforms to address the challenges of the immunosuppressive tumor microenvironment. Its lead candidate, KJ-01, targets Claudin 18.2 and is currently being evaluated in clinical trials for gastrointestinal cancers. Kejin Biotech aims to provide innovative and effective treatment options for patients with refractory solid malignancies through advanced cell engineering.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyT cell receptor engineered T cell therapyCell therapy
Industry: Biotech

Partnerships

Changhai Hospital

Beyond the preview

Go deeper on Wuxi Kejin Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuxi Kejin Biotechnology.

Explore the full profile